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As an alternative to antihelminthic drugs, we are exploiting vaccination to control infections with the
abomasal nematode Ostertagia ostertagi in cattle. Our focus for vaccine targets is excretory-secretory (ES)
products of this parasite. One of the most abundant antigens in larval and adult Ostertagia ES products is a
protein homologous to nematode polyprotein allergens. We found that the Ostertagia polyprotein allergen
(OPA) is encoded by a single-copy gene. OPA comprises three or more repeated units, and only the 15-kDa
subunits are found in ES products. The native antigen is localized in the intestinal cells of third-stage larvae
and in the hypodermis and cuticle of fourth-stage larvae and adult parasites. Vaccination of cattle with native
OPA (nOPA) in combination with QuilA resulted in protection against Ostertagia challenge infections. The
geometric mean cumulative fecal egg counts in the nOPA-vaccinated animals were reduced by 60% compared
to the counts in the control group during the 2-month course of the experiment. Both male and female adult
worms in nOPA-vaccinated animals were significantly shorter than the worms in the control animals. In the
abomasal mucus of vaccinated animals the nOPA-specific immunoglobulin G1 (IgG1) and IgG2 levels were
significantly elevated compared to the levels in the control animals. Reductions in the Ostertagia egg output and
the length of the adult parasites were significantly correlated with IgG1 levels. IgG2 titers were only negatively
associated with adult worm length. Protected animals showed no accumulation of effector cells (mast cells,
globular leukocytes, and eosinophils) in the mucosa. In contrast to the native antigen, recombinant OPA
expressed in Escherichia coli did not stimulate any protection.
At present, the control of Ostertagia ostertagi infections in
cattle largely depends on the use of chemical antihelminthic
drugs. Residues of introduced chemicals in foodstuffs and the
environment have become a serious consumer concern. Re-
ports of resistance to antiparasitic drugs for a closely related
parasite, Cooperia species, in cattle (5, 31) make the develop-
ment of alternative control systems even more urgent.
Early attempts to protect cattle against the abomasal nem-
atode O. ostertagi with irradiated larval vaccines (2) or with
crude somatic (12) and excretory-secretory (ES) products (13)
were not successful. Moderate levels of protection were ob-
tained in calves immunized with gut membrane glycoproteins
of O. ostertagi (24). Recently, it was shown that vaccination of
cattle with ES products of adult Ostertagia worms enriched for
cysteine proteinases by thiol-Sepharose chromatography re-
duced the fecal egg counts by 60% compared to the counts in
the control group (11).
Generally, ES products are considered to be essential for the
development and survival of the parasite within the host and
are targets for vaccine development (17). Immunoscreening of
cDNA libraries of both larvae (third-stage larvae [L3] and L4)
and adults of Ostertagia with polyclonal rabbit serum raised
against ES products led to identification of 15 genuinely se-
creted proteins with potential protective capacities (28).
One of these ES antigens showed strong sequence homology
to nematode polyprotein allergens (NPAs) of Ascaris suum
(25), Dictyocaulus viviparus (1), and Toxocara canis (33). NPAs
are synthesized as tandemly repetitive polypeptides composed
of 10 or more NPA units and are posttranslationally cleaved at
consensus sites into 14-kDa subunits (reviewed in references
15 and 16). NPA units bind fatty acids and retinoids and may
play a role in lipid transport in the nematode. NPAs appear to
be secreted by parasitic nematodes and may be involved in
modification of the local inflammatory and immunological en-
vironment of the host tissues which they inhabit (15, 16).
Although NPAs (especially ABA-1 from Ascaris) have been
characterized in detail biochemically and molecularly (1, 3, 6,
21, 22, 32, 33), to our knowledge they have never been tested
as vaccines in protection trials. Interestingly, allergens (by def-
inition) induce an immunoglobulin E (IgE) antibody response
that leads to a type I hypersensitivity reaction similar to the
reaction which appears to be associated with protective im-
mune responses to helminth parasites (20). Also, because
NPAs are specific to nematodes and have no structural homo-
logues in mammals, they are suitable vaccine candidates.
The objectives of this study were first to molecularly char-
acterize the Ostertagia polyprotein allergen (OPA) (e.g., to
determine the genomic organization, expression pattern, and
immunolocalization) and then to investigate the protective ca-
pacities of both purified native OPA (nOPA) and recombinant
OPA (rOPA) in cattle challenged with O. ostertagi.
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MATERIALS AND METHODS
Southern blot hybridization and probe preparation. Genomic DNA (5 g)
(29) was digested overnight at 37°C with XbaI and EcoRI (Amersham Pharmacia
Biotech), separated on a 1% agarose gel, and transferred to a nylon membrane
(Hybond-N; Amersham Pharmacia Biotech). Hybridization was done overnight
at 65°C with a probe generated from OPA (EMBL accession no. Z46800) (Gene
Images random prime labeling module; Amersham Life Science), and this was
followed by nonradioactive detection with a Gene Images CDP-Star detection
module (Amersham Life Science). The sequence of the opa probe contains one
restriction site for EcoRI and no restriction site for XbaI. After hybridization the
blot was exposed to scientific X-OMAT imaging film for 2 h (Kodak, Rochester,
N.Y.).
Levels of expression of opa determined by real-time PCR. Levels of opa
mRNA in L3, L4, and adult Ostertagia were determined by real-time PCR with
the Lightcycler system by using an LC-Fast Start reaction mixture with SYBR
Green I (Roche Diagnostics). Three micrograms of total RNA, prepared by
using the TRIZOL reagent (GibcoBRL, Life Technologies), was converted into
first-strand cDNA with oligo(dT) primers (SuperScript choice system for cDNA
synthesis; GibcoBRL, Life Technologies). The reaction mixture (total volume, 20
l) consisted of a master mixture containing Taq DNA polymerase, a de-
oxynucleoside triphosphate mixture, and SYBR Green, 3 mM MgCl2, 5 pmol of
primer 5-AGATCGTATCGCAGTCGAG-3, 5 pmol of primer 5-CCCAAGC
TTGTAACCCTCTATGTGGAA-3), and 2 l of template cDNA (1/10 dilu-
tion). The subsequent steps were initial denaturation for 10 min at 95°C and then
40 cycles of denaturation for 18 s at 95°C, annealing for 25 s at 58°C, and
extension for 14 s at 72°C. All real-time PCRs were performed in quadruplicate.
The specificity of the PCR products was confirmed by melting curve analysis and
subsequent agarose gel electrophoresis. To correct for variations in efficiency of
the reverse transcription step and for differences in both RNA quality and RNA
quantity between samples, data were normalized with the actin housekeeping
gene. The relative amount of opa expression was plotted as a ratio ([number of
copies of the target opa gene/number of copies of the housekeeping gene] 
106). For quantification, opa was cloned into plasmids and included in each PCR.
Preparation of parasite ES products. ES products from exsheathed L3, L4,
and adult parasites were prepared as described previously (10). Protein samples
were dialyzed against phosphate-buffered saline (PBS) (150 mM, pH 7.4) before
use.
SDS-PAGE and Western blotting. Sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) and Western blotting were performed by using
standard techniques, essentially as described previously (28). Western blots were
probed with monospecific antibodies that were affinity purified from anti-adult
ES product rabbit serum (28) or with bovine serum (diluted 1:400 in 2% horse
serum [HS] in PBS-Tween [PBST]). The blots were developed with goat anti-
rabbit or rabbit anti-bovine horseradish peroxidase conjugate (Sigma-Aldrich, St.
Louis, Mo.) that was diluted 1:8,000 in 2% HS in PBST, and recognized antigens
were visualized by adding 0.05% 3,3-diaminobenzidine tetrachloride in PBS
containing 0.02% (vol/vol) H2O2.
Immunolocalization of OPA. L3, L4, and adult male and female O. ostertagi
parasites were embedded in Tissue-Tek (Sakura Finetek Europe B.V.) and
frozen in liquid nitrogen. Twelve-micrometer-thick cryosections (Jung CM3000
cryotome; Leica Instruments GmbH) were mounted on 3-aminopropyltriethox-
ysilane (Sigma-Aldrich)-coated glass slides. The tissues were fixed in acetone for
10 min at 20°C and air dried. The endogenous peroxidase activity was blocked
by incubation of the slides in methanol containing 1.7% hydrogen peroxide for 10
min in the dark. Nonspecific binding was blocked for 30 min with 10% HS in
PBS. The slides were incubated with monospecific antibodies against OPA (28)
for 4 h at 37°C. To wash away unbound antibodies, the slides were incubated in
PBS with gentle shaking (three times for 10 min). Detection was done with Alexa
Fluor 594 goat anti-rabbit IgG(HL) (Molecular Probes) at a final concentra-
tion of 0.5 g/ml for 1 h at room temperature. Red fluorescence was detected by
absorption of green light with a Leitz DMRB light microscope (Leica Instru-
ments GmbH). Four negative controls were included; monospecific OPA anti-
bodies were replaced with 2% HS (conjugate control), monospecific OPA anti-
bodies were replaced with negative (preimmune) rabbit serum (at a 1/2,000
dilution in 2% HS), monospecific OPA antibodies were replaced with antiscabies
rabbit serum (at a 1/2,000 dilution in 2% HS), and the conjugate was replaced
with 2% HS.
Gel filtration chromatography. Thirty-milligram portions of L3 ES products
(650 g/ml; 3-ml samples) were loaded on a Sephadex G-50 Superfine gel
filtration column (70 by 1.6 cm; Pharmacia Biotech, Uppsala, Sweden) at a
concentration of 0.3 ml/min. The samples were eluted at 4°C with 10 mM
Tris–150 mM NaCl (pH 7.4) at a rate of 0.5 ml/min. Spectrophotometric detec-
tion was done at 280 nm. The collected fractions were evaluated by Western blot
analysis by using monospecific OPA antibodies (28). The OPA fractions were
pooled and concentrated with a Millipore Ultrafree-15 centrifuge filter unit
(Sigma-Aldrich). The purity of nOPA was verified by SDS-PAGE followed by
Coomassie blue staining. The yield of the purified nOPA was determined by the
bicinchoninic acid method (Pierce Chemical Co., Rockford, Ill.). Aliquots (100
g) of nOPA were stored at 70°C until they were used.
Cloning and expression of rOPA. A 1,212-bp cDNA fragment (EMBL acces-
sion no. Z46800) coding for the C-terminal part of OPA and isolated as de-
scribed above (28) was initially cloned in the pGEMT-easy vector (Promega
Corporation, Madison, Wis.). BamHI and XhoI restriction sites were introduced
by PCR (35 cycles of 1 min at 95°C, 1 min at 46°C, and 1.5 min at 72°C with final
extension for 10 min at 72°C) onto plasmid DNA (Qiagen plasmid Midi kit;
Westburg) by using primers OPAforward (5-GGATCCCATTCACTTGAAGA
CGCA-3) and OPAreverse (5-CTCGAGCTATGTGGAACGCGT-3). Diges-
tion of the expression vector pGEX-6P-1 (Amersham Pharmacia Biotech) with
BamH1 and XhoI permitted unidirectional cloning of opa. The constructs were
transformed into competent Escherichia coli BL21, and transformants were se-
lected. Selected constructs were verified by restriction digestion and sequence
analysis (PE Biosystems). Expression of OPA was induced by addition of 0.1 mM
isopropyl--D-thiogalactopyranoside (IPTG) for 2 h at 37°C. The glutathione
S-transferase fusion protein was purified by affinity chromatography by using a
glutathione Sepharose 4B column (Amersham Pharmacia Biotech). The gluta-
thione S-transferase affinity tail was removed by PreScission protease cleavage.
The concentration of rOPA was determined by the bicinchoninic acid method
(Pierce Chemical Co.). The purity of rOPA was verified by SDS-PAGE followed
by Coomassie blue staining. Aliquots (100 g) of rOPA were stored at 70°C
until they were used.
MALDI-TOF mass spectrometry analysis. The purified nOPA and rOPA
protein bands were excised from a one-dimensional SDS-PAGE gel and digested
in the gel with trypsin. The sets of peptides generated were mixed with matrix
molecules, spotted on an AnchorChip target, and analyzed by matrix-assisted
laser desorption ionization (MALDI) coupled to a time of flight (TOF) tube. The
identity of OPA was determined by comparing its peptide mass fingerprint with
the theoretical molecular weights of peptides that were produced by in silico
digestion of each of the protein sequences in the database (EMBL accession no.
Z46800).
Vaccination trial. A vaccination trial was designed essentially as described
previously (11). Three groups of seven male MontBe´liard calves that were 8
months old were randomly composed. All animals were vaccinated three times by
intramuscular injection at 3-week intervals either with 100 g of nOPA mixed
with 750 g of QuilA, with 100 g of rOPA mixed with 750 g of QuilA, or with
750 g of QuilA as an adjuvant control. Immunogens were randomly assigned to
the treatment groups, and the animals were examined daily for adverse reactions
to the immunizations. A trickle infection with 1,000 O. ostertagi L3 started on the
day of the last immunization and was administered for 25 days (5 days/week).
FIG. 1. Recognition pattern of OPA: Western blot of L3 ES prod-
ucts (lane A), L4 ES products (lane B), and adult ES products (lane C)
developed with monospecific antibodies against OPA and Western
blot of L3 ES products developed with sera of preimmune animals
(lane D), primary infected animals (lane E), and naturally immune
animals (lane F).
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Blood was collected at weekly intervals. Fecal egg counts were determined three
times a week (McMaster; sensitivity, 25 eggs per g) (26) starting 21 days postin-
fection and lasting until the animals were euthanized 36 days later. Parasitolog-
ical parameters, such as cumulative fecal egg counts, number and size of adult
worms, and number of eggs per adult female, were determined by using standard
techniques as described previously (11). All parasitological techniques were
performed blindly.
Ostertagia antibody detection by microplate ELISA. Local IgG1, IgG2, IgA,
IgE, and IgM levels against Ostertagia L3 ES products or nOPA were determined
by an enzyme-linked immunosorbent assay (ELISA). Ostertagia L3 ES products
(4 g/ml) or purified nOPA (0.5 g/ml) was coated overnight in carbonate buffer
(0.025 M, pH 9.6) and incubated in duplicate with an abomasal mucus extract
(100 g in PBS) from all animals. Mucus homogenates were prepared as de-
scribed previously (11).
Monoclonal antibodies against bovine immunoglobulins were obtained from
the ILRI Institute (Nairobi, Kenya) and diluted 1:2,500 (IgG1 and IgM), 1:5,000
(IgA), and 1:25,000 (IgG2) in PBS. Goat anti-mouse IgG coupled to horseradish
peroxidase (Sigma) was used as a conjugate (diluted 1:4,000 [IgG1, IgG2, and
IgM] or 1:8,750 [IgA] in PBS). O-Phenylenediamine (0.1% in citrate buffer) was
used as the substrate. IgE levels were determined as described previously (19).
Optical density was measured at 492 nm.
Histochemistry. Two random samples of mucosal tissue for histological exam-
ination were taken from the abomasal fundus at necropsy. The tissue sample
used for eosinophil and globule leukocyte staining was fixed with 4% parafor-
maldehyde in PBS at pH 7.4 for 6 h. The tissue sample used for mast cell
counting was fixed in Carnoy’s fluid for 4 h. After fixation, the tissues were
dehydrated and embedded in paraffin. Five sections that were 8 m thick were
collected from each sample by systematic randomization (14). The sections for
mast cell counting were stained with 0.25% toluidine blue. To obtain eosinophil
and globular leukocyte counts, the sections were stained by the carbol chromo-
trope technique. In the first section, three digital photographs of the musocal
layer were randomly taken, and two digital photographs of the submucosal layer
were taken. In the following four sections, the number of photographs alternated
(two and three photographs, three and two photographs, two and three photo-
graphs, and three and two photographs in the mucosa and submucosa, respec-
tively), which resulted in 13 pictures of the mucosa and 12 pictures of the
submucosa for each animal. The numbers of mast cells were determined in the
FIG. 2. Immunolocalization of OPA. Sections of L3 (A and B), L4 (C and D), and male (E and F) and female (G and H) adult O. ostertagi
parasites were incubated with monospecific antibodies to OPA, and antibody binding was detected by using Alexa Fluor-conjugated anti-rabbit
immunoglobulin. Female adult O. ostertagi parasites were also incubated with negative (preimmune) rabbit serum (at a 1/2,000 dilution in 2% HS)
(I). Panels A, C, E, and G are phase-contrast micrographs, and panels B, D, F, H, and I are fluorescence microscopy micrographs (signal indicated
by red fluorescence except in panel I). ic, intestinal cells; i, intestine; g, gonads; h, hypodermis; c, cuticle. Bars  25 m.
TABLE 1. Real-time PCR results: Numbers of copies of opa and
the actin gene in the different life stages
(L3, L4, and adult) of Ostertagiaa
Stage No. of copiesof opa
No. of copies
of actin gene
No. of copies of opa/no.
of copies of actin gene
(106)
L3 3.41  102 1.51  105 2,258
L4 4.66  101 3.38  103 1,378
Adult 6.6  103 1.09  107 605
a The relative amount of opa expression was determined as a ratio ([number of
copies of target opa/number of copies of the housekeeping gene]  106).
VOL. 72, 2004 OSTERTAGIA PROTECTIVE ANTIGEN OPA 2997
mucosa and submucosa of each animal by examining areas of approximately
1,014,000 and 936,000 m2, respectively. The numbers of globule leukocytes and
eosinophils were counted in the mucosa and submucosa by examining areas of
approximately 451,000 and 413,000 m2, respectively. The numbers of cells in
the mucosa and submucosa were expressed as numbers of cells per 100,000 m2
of microscopic field.
Statistical analysis. The significance of differences in parasitological parame-
ters (cumulative fecal egg counts, adult worm counts, adult worm lengths, num-
bers of eggs per female worm) and immunological parameters (mucosal antibody
levels and mast cell, globular leukocyte, and eosinophil counts) between groups
was investigated by performing Kruskal-Wallis one-way analysis of variance,
followed by a one-tailed Mann-Whitney U test for pairwise comparison of each
vaccinated group with the adjuvant control group. The correlation between the
different parasitological and immunological parameters was examined by using
Spearman’s correlation test. A P value of 0.05 was considered statistically
significant.
RESULTS
Molecular characterization of nOPA: genomic organization,
size, expression and recognition patterns, and immunolocal-
ization. Southern blot hybridization analysis of XbaI-digested
and EcoRI-digested Ostertagia genomic DNA with the OPA
probe (EMBL accession no. Z46800) resulted in detection of
one major band at approximately 12 kb and two prominent
bands at 3.8 and 1.8 kb, respectively (data not shown).
Western blots of somatic extracts from L3, L4, and adult O.
ostertagi developed with monospecific antibodies against OPA
revealed a ladder-like pattern of reactive bands, and each band
was approximately 14 kDa larger than the previous band (14,
28, and 42 kDa) (reference 7 and data not shown). On Western
blots of ES products from the three parasitic Ostertagia life
stages probed with the same monospecific OPA antibodies,
specific recognition of the 14-kDa protein band was detected in
all life stages (Fig. 1, lanes A, B, and C). This developmental
expression pattern was confirmed by real-time PCR. The high-
est levels of expression were detected in L3, and these levels
were approximately two- and fourfold higher than the levels in
the L4 and adult life stages, respectively (Table 1). A Western
blot of L3 ES products demonstrated that OPA was not rec-
ognized by serum antibodies of preimmune animals (Fig. 1,
lane D), was hardly recognized by serum of primary infected
animals (helminth-free calves which received a natural chal-
lenge infection for 3 weeks) (Fig. 1, lane E), and was very
strongly recognized by serum antibodies of immune animals
(Fig. 1, lane F) (animals that were naturally infected for two
grazing seasons, each of which was approximately 6 months
long).
On sections of Ostertagia parasites clear red fluorescence
was observed in the intestinal cells of L3 animals (Fig. 2B), in
the cuticle of L4 animals (Fig. 2D), and in the cuticle and
hypodermis of both male and female adult worms (Fig. 2F and
H).
No fluorescence was detected in sections of Ostertagia de-
veloped with preimmune rabbit serum (Fig. 2I) or with the
irrelevant rabbit serum (antiscabies serum) or in the conjugate
controls (data not shown).
Protein profiles of nOPA and rOPA and amino acid se-
quences. The yield of purified nOPA was around 10% of the
total L3 ES products. The yield of rOPA was 1.44 mg/liter. The
protein profiles of both nOPA and rOPA obtained by reducing
SDS-PAGE and Coomassie blue staining are shown in Fig. 3.
The nOPA fraction produced one main band at 14 kDa (Fig.
3, lane A). Although a strong 45-kDa protein band was pro-
duced by the rOPA fraction, two additional bands (at approx-
imately 30 and 14 kDa) were visible on the gel (Fig. 3, lane B).
The amino acid sequences of all visible bands, as determined
by MALDI-TOF mass spectrometry analysis, showed that all
of the protein bands represented nOPA or rOPA. The nOPA
band, however, comprised traces of a protein homologous to a
17-kDa L3 ES antigen of Ostertagia (EMBL accession no.
AJ318472).
Vaccination trial. No adverse reactions to the immuniza-
tions and no clinical signs of ostertagiosis were observed during
the vaccination trial. The fecal egg counts during the course of
the trial are expressed as geometric means in Fig. 4. During the
whole vaccination trial the geometric mean egg counts for the
nOPA-vaccinated animals were below the geometric mean
number of eggs per gram for the control QuilA group, which
resulted in a significant (60%) reduction (P  0.001) in the
cumulative number of eggs per gram (Table 2). In contrast,
there was a trend toward higher geometric values for the num-
ber of eggs per gram for the rOPA-vaccinated animals com-
pared to the values for the control QuilA group, although the
difference was not statistically significant. The results of the
other parasitological tests are summarized in Table 2. There
was not a significant difference in the number of adult worms
among the three groups. Both female and male adult worms
were significantly shorter in the nOPA-vaccinated animals (P
 0.001). This effect was not observed in the rOPA group. The
percentages of inhibited L4 and the numbers of eggs per fe-
male were similar for all three groups.
Immunological parameters. To monitor the antibody re-
sponse to the vaccine, Western blots of nOPA and rOPA were
developed with serum taken from all animals 1 week after the
second immunization (Fig. 5). No antibodies to nOPA or
rOPA were detected in serum from the control QuilA group
FIG. 3. Protein profile of OPA. After reducing SDS-PAGE nOPA
(lane A) and rOPA (lane B) were visualized by Coomassie blue stain-
ing.
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(Fig. 5A). While serum from nOPA-vaccinated animals specif-
ically recognized nOPA (Fig. 5B), serum antibodies from
rOPA-vaccinated animals bound only to the rOPA protein
bands (Fig. 5C). There was no cross-recognition between the
nOPA- and rOPA-vaccinated groups.
The experiments in which we determined the levels of abo-
masal immunoglobulin against total L3 ES products and nOPA
by ELISA produced similar results. Both nOPA- and rOPA-
vaccinated animals had significantly higher IgG1 titers in the
mucus than the adjuvant control group had (Table 3). Elevated
IgG1 levels were negatively correlated with the cumulative
number of eggs per gram (Spearman’s rho value, 0.448) and
the lengths of male and female adult worms (Spearman’s rho
values, 0.654 and 0.630, respectively). Moreover, signifi-
cantly greater IgG2 responses were evident in the protected
animals, and these responses were negatively correlated with
the length of the female adult parasites (Spearman’s rho val-
ues, 0.374 and 0.429, respectively). There was not a statis-
tically significant difference in the IgA, IgE, and IgM levels
among the three groups (Table 3).
The numbers of mast cells in the vaccinated animals and the
control group were not significantly different (Table 3). Both
the mean numbers of globular leukocytes and the mean num-
bers of eosinophils were significantly lower in the vaccinated
animals than in the adjuvant control group. No correlations
between effector cell types and parasitological parameters
were found (data not shown).
DISCUSSION
In this paper we describe molecular characterization of
OPA, an Ostertagia polyprotein, and its potential to induce
protection against homologous infection in cattle.
The organization of the coding sequence of opa in genomic
DNA of Ostertagia could indicate that there is only one copy of
the opa gene. This is the case for the genes encoding NPAs of
other nematodes, such as Dirofilaria immitis (6), Brugia pahangi
(27), Brugia malayi (27), and D. viviparus (1). The nOPA an-
tigen was located in the intestinal cells of Ostertagia L3 and in
the cuticle and hypodermis of L4 and adult parasites. Similarly,
FIG. 4. Geometric mean number of eggs per gram (Geomean EPG). Fecal egg output was determined during the trial for nOPA vaccinated-,
rOPA vaccinated-, and control animals.
TABLE 2. Parasitological parameters
Group n Geometric mean cumulativeno. of eggs per g (range)
Geometric mean no. of
worms (range)
Geometric mean worm length (mm)
(range) % of L4 (range)
Geometric mean no. of
eggs per female
(range)Females Males
Control 7 2,235 (1,300–3,338) 8,300 (3,100–14,000) 9.51 (9.26–9.67) 8.04 (7.91–8.07) 1 (0–1.38) 20 (15–29)
nOPA 7 914 (350–1,275)a 8,129 (6,150–11,250) 9.05 (8.59–9.38)b 7.61 (7.19–7.92)b 1 (0–1.62) 20 (16–23)
rOPA 7 2,780 (1,625–4,225) 9,464 (7,550–11,550) 9.33 (8.67–9.72) 7.82 (7.32–8.16) 1 (0–2.13) 21 (17–25)
a P  0.001.
b P  0.005.
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immunostaining of Di5 antigen, the OPA homologue of D.
immitis, was apparent in the hypodermis and the cuticle of the
parasite (22). In Caenorhabditis elegans, NPAs have been
found to bind fatty acids and retinol (reviewed in reference 15).
In parasitic nematodes however, the major function of NPAs is
to alter the host tissue environment to the parasites’ advantage
(16). The results of the immunolocalization analysis together
with the Western blot results indeed suggest that OPA is se-
creted. Release of OPA into the environment could occur
directly from the gut with the L3 stage or from the cuticle via
the hypodemis with Ostertagia L4 and adults.
Surprisingly, the protein profile of rOPA determined by
reducing SDS-PAGE and Coomassie blue staining contained
three bands (at 14, 30, and 45 kDa) instead of the one protein
band expected at 45 kDa. OPA and NPAs in general are
composed of a series of direct repeats with regularly spaced
proteolytic cleavage sites such that they are processed into
multiple polypeptides that are approximately 14 kDa long.
These proteolytic consensus cleavage sites consisting of four
amino acids match the motif K/R-X-K/R-R. It is known that
the use of certain codons (especially those coding for arginine)
is rare in E. coli, so it is possible that peptide synthesis is
retarded or even retained at the cleavage sites, resulting in
three partial recombinant proteins. This hypothesis is strength-
ened by the fact that the peptides generated from the 14-kDa
protein band in the MALDI-TOF mass spectrometry analysis
originated from the first 100 amino acids of OPA.
Despite the protective properties of the nOPA, no protec-
tive immune response was generated by vaccination with the
rOPA expressed in E. coli. Failure to induce protection may
have been due to the absence of specific posttranslational
modifications of nematode antigens which are essential for the
protective capacity of the antigens, and glycosylation is very
important (18). For example, IgE and IgA recognition of a
glycoprotein expressed on the surface of Teladorsagia circum-
cincta L3 is correlated with protective immunity but is almost
totally directed against the glycan component (18). It is also
possible that a full-length OPA is necessary for appropriate
conformation and thus for protection. Of course, we cannot
rule out the possibility that the second protein (EMBL acces-
sion no. AJ318472), although present at only minor levels, may
have contributed to the protection obtained with nOPA.
Our experiment confirms that systemic (intramuscular) vac-
cination in combination with QuilA as an adjuvant can induce
a mucosal immune response (11). A clear abomasal IgG1 and
IgG2 response was observed in both the nOPA- and rOPA-
vaccinated groups; however, the antibody titers were highest in
the nOPA-vaccinated animals. Because there was a negative
correlation between IgG titers and cumulative number of eggs
per gram or worm length, it is likely that a threshold level of
local antibodies is required for protection. In contrast to what
was expected, significantly lower numbers of globular leuko-
cytes and eosinophils were found in the vaccinated groups.
Surprisingly, vaccination with nOPA did not lead to higher IgE
levels, suggesting that nOPA is not intrinsically allergenic.
It is important to stress that an Ostertagia vaccine in cattle
needs to be an antifecundity vaccine (30). As the number of
worm eggs shed during the first part of the grazing season
determines the number of infective larvae in the pasture in the
second half of the grazing season, reduction in egg excretion
should be the target. Also, because the fecundity of Ostertagia
is highly regulated by host immunity (23) and fecal egg output
can be strongly reduced without a reduction in the number of
worms (9, 4), the number of eggs per gram is the best param-
eter for evaluation of the protective efficacy of Ostertagia an-
tigens (30). Analogous with observations on the effects of an-
tihelminthic boli on gastrointestinal nematodes in cattle (8), it
can be stated that vaccination with nOPA that results in a 60%
reduction in the number of eggs per gram for at least 2 months
FIG. 5. Serum antibody responses to the vaccine. Western blots of
nOPA (lanes 1, 3, and 5) and rOPA (lanes 2, 4, and 6) were developed
with pooled sera collected 1 week after the second immunization of
control animals (A), nOPA-vaccinated animals (B), and rOPA-vacci-
nated animals (C).
TABLE 3. Immunological parameters
Group n
Mucosal nOPA-specific levels (mean 	 SD) ofa: No. (mean 	 SD) ofb:
IgG1 IgG2 IgA IgE IgM Mucosal mastcells Globular leukocytes Eosinophils
Control 7 0.145 	 0.018 0.151 	 0.017 0.399 	 0.234 0.230 	 0.027 0.228 	 0.042 9.624 	 2.925 3.769 	 3.473 7.921 	 3.950
nOPA 7 0.257 	 0.092c 0.315 	 0.147c 0.527 	 0.347 0.232 	 0.014 0.247 	 0.024 10.02 	 3.924 2.35 	 4.197d 2.23 	 4.345c
rOPA 7 0.183 	 0.027c 0.256 	 0.109d 0.488 	 0.176 0.225 	 0.027 0.258 	 0.036 9.65 	 2.877 1.87 	 2.916d 2.79 	 3.090d
a Determined by ELISA.
b Number of cells per 100,000 m2 of microscopic field.
c P  0.01.
d P  0.05.
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is sufficient to protect first-grazing-season calves from osterta-
giosis without interfering with the development of natural im-
munity.
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